JP2023513833A5 - - Google Patents
Info
- Publication number
- JP2023513833A5 JP2023513833A5 JP2022549318A JP2022549318A JP2023513833A5 JP 2023513833 A5 JP2023513833 A5 JP 2023513833A5 JP 2022549318 A JP2022549318 A JP 2022549318A JP 2022549318 A JP2022549318 A JP 2022549318A JP 2023513833 A5 JP2023513833 A5 JP 2023513833A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- composition
- seq
- sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062978201P | 2020-02-18 | 2020-02-18 | |
| US62/978,201 | 2020-02-18 | ||
| PCT/US2021/018561 WO2021168100A1 (en) | 2020-02-18 | 2021-02-18 | Formulations of human anti-tslp antibodies and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023513833A JP2023513833A (ja) | 2023-04-03 |
| JP2023513833A5 true JP2023513833A5 (https=) | 2024-02-27 |
Family
ID=74860588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549318A Pending JP2023513833A (ja) | 2020-02-18 | 2021-02-18 | ヒト抗ｔｓｌｐ抗体の製剤及びそれを使用する方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20230081261A1 (https=) |
| EP (1) | EP4106811A1 (https=) |
| JP (1) | JP2023513833A (https=) |
| KR (1) | KR20220143699A (https=) |
| CN (1) | CN115151276A (https=) |
| AR (1) | AR121368A1 (https=) |
| AU (1) | AU2021221998A1 (https=) |
| BR (1) | BR112022016456A2 (https=) |
| CA (1) | CA3167975A1 (https=) |
| CL (1) | CL2022002251A1 (https=) |
| CO (1) | CO2022013251A2 (https=) |
| CR (1) | CR20220465A (https=) |
| IL (1) | IL295511A (https=) |
| JO (1) | JOP20220193A1 (https=) |
| MX (1) | MX2022010120A (https=) |
| PE (1) | PE20230115A1 (https=) |
| PH (1) | PH12022552132A1 (https=) |
| TW (1) | TW202144004A (https=) |
| UY (1) | UY39089A (https=) |
| WO (1) | WO2021168100A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4145105A1 (de) * | 2021-09-06 | 2023-03-08 | Anacyte Laboratories GmbH | Lösung für die asservierung von zellen |
| WO2023040999A1 (zh) * | 2021-09-18 | 2023-03-23 | 江苏康宁杰瑞生物制药有限公司 | 包含pd-l1抗原结合片段的组合物及其用途 |
| CN116251181B (zh) * | 2021-12-02 | 2023-09-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp单克隆抗体的注射制剂 |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| TW202426485A (zh) * | 2022-10-26 | 2024-07-01 | 美商安進公司 | 抗ｔｓｌｐ抗體組成物及其用途 |
| EP4647084A1 (en) * | 2023-01-06 | 2025-11-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Method for treating asthma by using tslp antibody |
| IL324470A (en) * | 2023-05-18 | 2026-01-01 | Medimmune Llc | Treatment of corticosteroid-dependent asthma using anti-TSLP antibody |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| UY32038A (es) | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| ES2784123T3 (es) | 2009-11-04 | 2020-09-22 | Merck Sharp & Dohme | Anticuerpo anti TSLP genomodificado |
| PH12012501364A1 (en) * | 2010-01-15 | 2012-10-22 | Amgen K A Inc | Antibody formulation and therapeutic regimens |
| WO2012007495A1 (en) | 2010-07-15 | 2012-01-19 | F. Hoffmann-La Roche Ag | Antibodies specifically binding to human tslpr and methods of use |
| AT510032B1 (de) | 2010-11-30 | 2012-01-15 | Steiner Erwin Ing | Montageeinrichtung für fassadenelemente |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| KR20170123315A (ko) | 2015-03-11 | 2017-11-07 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Tslp 결합 단백질 |
| EA038332B1 (ru) * | 2015-09-09 | 2021-08-10 | Новартис Аг | Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул |
| KR102666879B1 (ko) * | 2017-04-12 | 2024-05-23 | 암젠 인크 | 항-tslp 항체를 이용한 천식의 치료 |
| EP3615065A1 (en) * | 2017-04-28 | 2020-03-04 | Amgen Inc. | Excipients to reduce the viscosity of antibody formulations and formulation compositions |
| JP7200134B2 (ja) | 2017-06-08 | 2023-01-06 | アムジエン・インコーポレーテツド | トルク駆動式薬物送達デバイス |
| MA50557A (fr) | 2017-11-10 | 2020-09-16 | Amgen Inc | Pistons pour dispositifs d'administration de médicament |
| EP4321870B1 (en) | 2018-03-13 | 2025-07-30 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| TW202541859A (zh) | 2018-10-15 | 2025-11-01 | 美商安進公司 | 具有阻尼機構之藥物遞送裝置及自動注射器 |
| WO2020081480A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Platform assembly process for drug delivery device |
-
2021
- 2021-02-18 IL IL295511A patent/IL295511A/en unknown
- 2021-02-18 AU AU2021221998A patent/AU2021221998A1/en active Pending
- 2021-02-18 US US17/760,470 patent/US20230081261A1/en active Pending
- 2021-02-18 CA CA3167975A patent/CA3167975A1/en active Pending
- 2021-02-18 WO PCT/US2021/018561 patent/WO2021168100A1/en not_active Ceased
- 2021-02-18 AR ARP210100423A patent/AR121368A1/es unknown
- 2021-02-18 UY UY0001039089A patent/UY39089A/es unknown
- 2021-02-18 TW TW110105518A patent/TW202144004A/zh unknown
- 2021-02-18 KR KR1020227031575A patent/KR20220143699A/ko active Pending
- 2021-02-18 MX MX2022010120A patent/MX2022010120A/es unknown
- 2021-02-18 PE PE2022001777A patent/PE20230115A1/es unknown
- 2021-02-18 CR CR20220465A patent/CR20220465A/es unknown
- 2021-02-18 JO JOP/2022/0193A patent/JOP20220193A1/ar unknown
- 2021-02-18 BR BR112022016456A patent/BR112022016456A2/pt active IP Right Grant
- 2021-02-18 CN CN202180015035.0A patent/CN115151276A/zh active Pending
- 2021-02-18 JP JP2022549318A patent/JP2023513833A/ja active Pending
- 2021-02-18 EP EP21710848.9A patent/EP4106811A1/en active Pending
- 2021-02-18 PH PH1/2022/552132A patent/PH12022552132A1/en unknown
-
2022
- 2022-08-18 CL CL2022002251A patent/CL2022002251A1/es unknown
- 2022-09-16 CO CONC2022/0013251A patent/CO2022013251A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023513833A5 (https=) | ||
| JP7277681B2 (ja) | 抗体処方物 | |
| US20230192873A1 (en) | Method of treating diseases using an il-17 receptor antibody formulation | |
| JP7080263B2 (ja) | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 | |
| AU2009324371B2 (en) | Antibody formulation | |
| JP2024178197A (ja) | 液体医薬組成物 | |
| IL302921A (en) | Anti-vegf protein compositions and methods for producing the same | |
| JP7551822B2 (ja) | 治療用抗体製剤 | |
| WO2015090162A1 (zh) | 一种含有阿达木单抗的药物组合物 | |
| JP2015522524A (ja) | 抗体製剤 | |
| JP2013543505A5 (https=) | ||
| JP2022097600A (ja) | 抗ＴＮＦα抗体の液状製剤 | |
| US20220062414A1 (en) | Stable Anti-OSMR Antibody Formulation | |
| US12565526B2 (en) | Formulations of anti-RSV antibodies and methods of use thereof | |
| WO2022135395A1 (zh) | 稳定的抗体制剂及其制备方法和应用 | |
| JP2023513312A5 (https=) | ||
| TWI866551B (zh) | 穩定抗體組合物 | |
| JP2023553538A5 (https=) | ||
| JP2019534287A (ja) | 治療計画 | |
| CA3115708C (en) | Formulations of anti-rsv antibodies and methods of use thereof | |
| JP2023514721A5 (https=) | ||
| JP2025516856A (ja) | 抗ｃｄ３８融合タンパク質製剤 | |
| WO2025129029A2 (en) | Combinations of foralumab with glucagon-like peptide 1 (glp-1) agonists or sodium-glucose cotransporter-2 (sglt2) inhibitors and methods of use thereof | |
| CN118078988A (zh) | 包含靶向il-17a的抗体药物组合物 | |
| TW202434295A (zh) | 一種靶向ｔｓｌｐ的單殖株抗體製劑 |